Substance / Medication

Sulfinpyrazone

Overview

Active Ingredient
sulfinpyrazone
RxNorm CUI
10205

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

25 trials linked to this intervention

25
Total Trials
7
Recruiting
13
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Effects of bariatric surgery on hyperuricemia and gout: a systematic review of the literature.
Soricelli Emanuele, Quartararo Giovanni, Leuratti Luca et al. · Updates Surg · 2025
PMID: 39520613Meta-Analysis
Phytochemical compounds for treating hyperuricemia associated with gout: a systematic review.
Chenchula Santenna, Ghanta Mohan Krishna, Alhammadi Munirah et al. · Naunyn Schmiedebergs Arch Pharmacol · 2025
PMID: 39636406Meta-Analysis
Sulfinpyrazone reduces cyclosporine levels: a new drug interaction in heart transplant recipients.
Caforio A L, Gambino A, Tona F et al. · J Heart Lung Transplant · 2000
PMID: 11124491Observational
Usefulness of Optimized Human Fecal Material in Simulating the Bacterial Degradation of Sulindac and Sulfinpyrazone in the Lower Intestine.
Kostantini Christina, Arora Sumit, Söderlind Erik et al. · Mol Pharm · 2022
PMID: 35729720Other
Sulfinpyrazone C-glucuronidation is catalyzed selectively by human UDP-glucuronosyltransferase 1A9.
Kerdpin Oranun, Elliot David J, Mackenzie Peter I et al. · Drug Metab Dispos · 2006
PMID: 16985098Other
Free radical scavenging properties of sulfinpyrazone.
Yang Mei-Ling, Huang Tien-Shang, Lee Yashang et al. · Free Radic Res · 2002
PMID: 12180194Other
Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s.
He M, Rettie A E, Neal J et al. · Drug Metab Dispos · 2001
PMID: 11302937Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Sulfinpyrazone (substance)
SNOMED CT
387108008
UMLS CUI
C0038742
RxNorm CUI
10205

Clinical Data

This intervention maps to 9 entities in the Ltrl knowledge graph.

3
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
25
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Sulfinpyrazone — Conditions, Biomarkers & Specialists | Ltrl | Healos